Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Recombinant COVID-19 Variant Vaccine (WSK-V102) Booster
NCT05770180Phase 2Completed
- Sponsor
- WestVac Biopharma
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant COVID-19 variant vaccine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by WestVac Biopharma. Primary endpoints: Solicited Adverse Events at 14 days and Primary Immunogenic Indicator at 14 days. Started Mar 2023; status: completed.
02
Drugs
recombinant COVID-19 variant vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05770180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770180.